veteran using Nerivio at VA office

The Department of Veterans Affairs reports that veterans are more likely to experience migraine than civilians.1

The Global Burden of Disease (GBD) study of 2016 ranks migraine, in years of life lived with disability, as the second most disabling disorder globally.2

Nerivio VA Ordering Information
veteran using Nerivio at VA office mobile

To order Nerivio, please follow these steps

1. Medical Provider submits order to Prosthetics/Pharmacy

Product Nerivio Refill pack for Nerivio
Item # FGD000075 Dev-NM-0120
FSS # 36F79721D0103 36F79721D0103
# of devices _____________ _____________

2. Prosthetics/Pharmacy faxes PO

Submit all POs for Nerivio by Fax to

FAX: 877-646-9848 or

Email: aouellette@procarerx.com

ProCare customer service tel: 702-588-2911

Drug-free, easy-to-use, non-invasive device for the acute treatment of migraine

female veteran waring Nerivio
female veteran waring Nerivio

EFFECTIVE

66.7% of patients  found relief from their migraine pain at 2 hrs post treatment.3

SAFE

96.4% of patients studied did not report any device related side effects.3

EASY-TO-USE

89.7% of patients opted to treat with REN (Nerivio) to avoid medication use.4

Clinical dataMechanism of Action (MOA)

Nerivio is indicated for migraine patients 12 years of age or older. Nerivio should not be used by people with congestive heart failure, severe cardiac or cerebrovascular disease, or uncontrolled epilepsy.  Nerivio should not be used by anyone with active implantable medical devices (eg, pacemaker, hearing aid implant). It should only be applied on the upper arm over dry, healthy skin with normal physical sensation and without any metallic implants or in proximity to cancerous lesions. Nerivio has not been evaluated in pregnancy or those under the age of 12.

  1. https://americanmigrainefoundation.org/resource-library/veterans-and-migraine/
  2. GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):954-976. doi:10.1016/S1474-4422(18)30322-3
  3. Yarnitsky D, Dodick DW, Grosberg BM, Burstein R, Ironi A, Harris D, Lin T, Silberstein SD. Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Headache. 2019;59(8): 1240-1252
  4. Marmura MJ, Lin T, Harris D, lroni A, Rosen NL. Incorporating Remote Electrical Neuromodulation (REN) Into Usual Care Reduces Acute Migraine Medication. Use: An Open-Label Extension Study. Frontiers in Neurology. 2020; 11 :226